Abstract
Background/Aims: Our understanding of the effectiveness of cardioprotective medications in maintenance dialysis patients is based upon drug exposures assessed at a single point in time. We employed a novel, time-dependent approach to modeling medication use over time to examine outcomes in a large national cohort. Methods: We linked Medicaid prescription claims with United States Renal Data System registry data and Medicare claims for 52,922 hypertensive maintenance dialysis patients. All-cause mortality and a combined cardiovascular disease (CVD)-endpoint were modeled as functions of exposure to cardioprotective antihypertensive medications (renin angiotensin system antagonists, β-adrenergic blockers, and calcium channel blockers) measured with three time-dependent covariates (weekly exposure status, proportion of prior weeks with exposure, and number of switches in exposure status) and with propensity adjustment. Results: Current cardioprotective medication exposure status as compared to not exposed was associated with lower adjusted hazard ratios (AHRs) for mortality, though the magnitude depended upon the proportion of prior weeks with medication (duration) and the number of switches between active and non-active use (switches) (AHR range 0.54-0.90). Combined CVD-endpoints depended upon the proportion of weeks on medication: AHR = 1.18 for 10% and AHR = 0.90 for 90% of weeks. Combined CVD-endpoint was also lower for patients with fewer switches. Conclusions: Effectiveness depends not only on having a drug available but is tempered by duration and stability of use, likely reflecting variation in clinical stability and patient behavior.
References
1.
Lopes AA, Bragg-Gresham JL, Ramirez SP, Andreucci VE, Akiba T, Saito A, et al: Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant 2009;24:2809-2816.
2.
United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2006.
3.
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
4.
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF): Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-2007.
5.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
6.
Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
7.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
8.
Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-1498.
9.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
10.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
11.
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
12.
Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, et al: Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004;292:2849-2859.
13.
Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, et al: Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005;294:1794-1798.
14.
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
15.
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
16.
Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
17.
Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
18.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
19.
Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009;373:1009-1015.
20.
Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009;53:860-866.
21.
Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG: Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014;29:672-681.
22.
Wetmore JB, Shireman TI: The ABCs of cardioprotection in dialysis patients: a systematic review. Am J Kidney Dis 2009;53:457-466.
23.
Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004;164:2465-2471.
24.
Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784-1790.
25.
Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003;42:1260-1269.
26.
Ishani A, Herzog CA, Collins AJ, Foley RN: Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 2004;65:1017-1025.
27.
Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002;61:2157-2164.
28.
Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC: Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002;62:1799-1805.
29.
Berger AK, Duval S, Krumholz HM: Aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-208.
30.
Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG: Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton) 2003;8:177-183.
31.
Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-1029.
32.
McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and β-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002;144:226-232.
33.
Tepel M, Giet MV, Park A, Zidek W: Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) 2002;103:511-515.
34.
Winkelmayer WC, Charytan DM, Levin R, Avorn J: Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 2006;47:301-308.
35.
Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC: Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-1277.
36.
Boger CA, Gotz AK, Kruger B, Hosl M, Schmitz G, Riegger GA, et al: Effect of genetic variation on therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res 2005;10:161-168.
37.
Rigler SK, Wetmore JB, Mahnken JD, Dong L, Ellerbeck EF, Shireman TI: Impact of a modified data capture period on Liu comorbidity index scores in Medicare enrollees initiating chronic dialysis. BMC Nephrol 2013;14:51.
38.
Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010;77:141-151.
39.
Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, et al: Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45(suppl 2):S131-S142.
40.
Eggers PW: CMS 2728: what good is it? Clin J Am Soc Nephrol 2010;5:1908-1909.
41.
Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, et al: Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000;11:520-529.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
